Wave Life Sciences Ltd - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
WVE Nasdaq 8731 https://www.wavelifesciences.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Wave Life Sciences Ltd

Wave Life Sciences to Present at the 2022 Jefferies Healthcare Conference - May 25th, 2022 12:30 pm
Ahead Of Upcoming Data On Three Programs, Analysts Remain On Sidelines For Wave Life Sciences - May 13th, 2022 6:51 pm
Wave Life Sciences (WVE) Reports Q1 Loss, Lags Revenue Estimates - May 12th, 2022 12:45 pm
Wave Life Sciences Reports First Quarter 2022 Financial Results and Provides Business Update - May 12th, 2022 11:30 am
Wave Life Sciences to Present at Upcoming Investor Conferences - May 10th, 2022 12:30 pm
Here's Why We're Watching Wave Life Sciences' (NASDAQ:WVE) Cash Burn Situation - May 5th, 2022 5:21 pm
Wave Life Sciences to Webcast Conference Call of First Quarter 2022 Financial Results on May 12, 2022 - May 5th, 2022 12:30 pm
Wave Life Sciences Announces Publication of Foundational Preclinical Data Supporting Development of WVE-004 for C9orf72-associated ALS and FTD - Apr 25th, 2022 12:30 pm
Wave Life Sciences to Present at Chardan’s 6th Annual Genetic Medicines and Cell Therapy Manufacturing Summit - Apr 19th, 2022 12:30 pm
Wave Life Sciences Jump As Low Doses of WVE-004 Lowers Disease Biomarker In Neurological Indications - Apr 4th, 2022 4:16 pm
Wave Life Sciences Announces Positive Update to Ongoing Phase 1b/2a FOCUS-C9 Study Driven by Potent, Durable Reductions of Poly(GP) with Low, Single Doses of WVE-004 - Apr 4th, 2022 11:30 am
Wave Life Sciences to Present at Stifel 2022 CNS Days - Mar 21st, 2022 12:30 pm
Athira Pharma Announces Appointment of Dr. Michael A. Panzara to its Board of Directors - Mar 21st, 2022 11:05 am
Wave Life Sciences to Highlight RNA Base Editing Modality and Alpha-1 Antitrypsin Deficiency Program at Upcoming Scientific and Industry Meetings - Mar 15th, 2022 12:30 pm
Wave Life Sciences Announces Nature Biotechnology Publication Highlighting First RNA Base Editing in Non-Human Primates Using an Endogenous Enzyme - Mar 7th, 2022 4:14 pm
Wave Life Sciences (WVE) Reports Q4 Loss, Misses Revenue Estimates - Mar 3rd, 2022 1:45 pm
Wave Life Sciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update - Mar 3rd, 2022 12:30 pm
Albireo Pharma (ALBO) Reports Q4 Loss, Tops Revenue Estimates - Mar 1st, 2022 3:25 pm
Wave Life Sciences to Webcast Conference Call of Fourth Quarter and Full Year 2021 Financial Results on March 3, 2022 - Feb 24th, 2022 1:30 pm
Adaptive Biotechnologies (ADPT) Reports Q4 Loss, Tops Revenue Estimates - Feb 15th, 2022 10:55 pm